Compare The Coca-Cola Co K (KO) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? The Coca-Cola Co K trades at $92.34 (market cap $387.70B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: The Coca-Cola Co K is far larger — about 398.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and The Coca-Cola Co K pays a 2.35% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold The Coca-Cola Co K for 154 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| KO | MRVI | |
|---|---|---|
Market Cap | $387.70B | $972.90M |
Volume | 15,313,783 | 4,325,710 |
Sector | Consumer Staples | Health |
52-Week High | $91.99 | $9.00 |
52-Week Low | $67.08 | $2.83 |
Typical Hold Time | 154 Days | 0 Days |
Enterprise Value | $414.87B | $1.08B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $91.78, up 2.22% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $95.75. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.97 exceeding expectations, and maintains robust profitability with a 28.56% net income margin. Recent news highlights institutional buying and stable demand trends, though RSI levels indicate potential near-term overbought conditions.
The stock offers a solid dividend profile with 64 consecutive years of increases, but faces risks from regional demand divergence and high valuation multiples. Upside is supported by earnings momentum and institutional accumulation, while macroeconomic pressures and elevated P/E of 27.06 pose caution. The balance between growth execution and market sentiment will drive near-term performance.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
